ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings
Executive Summary
The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.
You may also be interested in...
J&J's Quad HIV Combo Likely To Pass CHMP; EU Market Uptake Is Trickier
Johnson & Johnson's quadruple HIV combination is likely to win a positive recommendation for approval in Europe this week – but clever positioning will be required to secure strong uptake for the combination considering its late entry onto a competitive market place.
Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen
The latest HIV drug development news and highlights from our FDA Performance Tracker.
Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?
Having lost market share in recent years to HIV regimens containing ViiV's Tivicay, will a showing of non-inferiority across four head-to-head Phase III studies give bictegravir the market edge Gilead seeks?